Market Applicability							
Market	**DC**	**GA**	**KY**	**MD**	**NJ**	**NY**	**WA**
Applicable	X	X	X	X	X	X	X

Lartruvo (olaratumab)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Lartruvo (olaratumab)

APPROVAL CRITERIA

Requests for Lartruvo (olaratumab) may be approved when the following criteria are met:

I. Individual has a diagnosis of Soft Tissue Sarcoma; **AND**
II. Individual has a histologically confirmed diagnosis of late stage soft tissue sarcoma (locally advanced or metastatic); **AND**
III. Individual has not previously treated with an anthracycline; **AND**
IV. Individual is unable to use radiotherapy or surgery is not a curative treatment option; **AND**
V. Individual's current Eastern Cooperative Oncology Group (ECOG) performance status is 0-2; **AND**
VI. If the individual is less than 18 years of age, Lartruvo is not used as first-line chemotherapy; **AND**
VII. Individual is using in combination with doxorubicin and, after at least 8 cycles with doxorubicin or earlier discontinuation of doxorubicin due to toxicity, and then if so chosen, continuing Lartruvo as monotherapy in the absence of unacceptable toxicities until disease progression.

Requests for Lartruvo (olaratumab) may not be approved if the following criteria are not met and for all other indications.

Market Applicability							
Market	**DC**	**GA**	**KY**	**MD**	**NJ**	**NY**	**WA**
Applicable	X	X	X	X	X	X	X

State Specific Mandates		
State name N/A	Date effective N/A	Mandate details (including specific bill if applicable) N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: http://www.clinicalpharmacology.com. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: April 13, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Gerber DE, Swanson P, Lopez-Chavez A, et al. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer. 2017. 111:108-115.
5. Hakenberg OW, Perez-Gracia JL, Castellano D et al, Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2019;107:186-195.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
7. McGuire WP, Penson RT, Gore, M et al. Randomized phase II study of the PDGFRa antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. BMC Cancer 2018; 18: 1292.
8. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: http://www.nccn.org/index.asp. Accessed on April 13, 2019.
    a. Soft Tissue Sarcoma (V.2.2019). Revised February 4, 2019